TNTox – Outcome und Toxizität nach totaler neoadjuvanter Therapie beim Rektumkarzinom-Reference-Cited by-同舟云学术

TNTox – Outcome und Toxizität nach totaler neoadjuvanter Therapie beim Rektumkarzinom

Published:2024-06-26 Issue:4 Volume:39 Page:304-307
ISSN:0947-0255
Container-title:Forum
language:de
Short-container-title:Forum

Author:

Wurschi Georg,Mäurer Matthias,Aninditha Kynann Putra,Becker Jan-Niklas,Bischoff Martin,Büttner Marcel,Cieslak Adrianna,Depardon Alina,Diefenhardt Markus,Edelmann Marcus,Ehret Felix,Fabian Alexander,Ferdinandus Simone,Fiegert Sean,Frerker Bernd,Heß Sebastian,Hlouschek Julian,Hoffmann Elgin,Irschfeld Lisa-Marie,Kaufmann Justus,Keßler Christopher,Rühle Alexander,Salfelder Maria-Elena,Schepers-von Ohlen Daphne,Schneider Melanie,Schöneich Maren,Schunn Fabian,Sonnhoff Mathias,Spohn Simon,Sprengel Simon David,Trommer Maike,Trommer Simon,Pietschmann Klaus

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12312-024-01339-4.pdf

Reference23 articles.

1. Glynne-Jones R et al (2017) Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol iv22(iv40):28

2. Sauer R et al (2004) Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N Engl J Med 351(17):1731–1740

3. Fokas E et al (2019) Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. JCO 37(34):3212–3222

4. Bahadoer RR et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42

5. Conroy T et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715